等待开盘 12-20 09:30:00 美东时间
-0.455
-26.30%
Pyxis Oncology released preliminary data from Phase 1 studies of MICVO for recurrent/metastatic head and neck squamous cell carcinoma.
12-19 22:07
U.S. stocks traded higher this morning, with the Dow Jones index gaining around...
12-18 22:47
RBC Capital analyst Leonid Timashev reiterates Pyxis Oncology (NASDAQ:PYXS) with a Outperform and maintains $7 price target.
2024-09-19 21:55